[{"id":"671af31b-ea72-43a1-a698-3450cef359b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05905341","created_at":"2023-06-15T17:08:34.937Z","updated_at":"2024-07-02T16:35:29.986Z","phase":"Phase 1","brief_title":"Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.","source_id_and_acronym":"NCT05905341","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • PF-07224826"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/15/2024","start_date":" 01/15/2024","primary_txt":" Primary completion: 04/14/2026","primary_completion_date":" 04/14/2026","study_txt":" Completion: 04/13/2028","study_completion_date":" 04/13/2028","last_update_posted":"2023-11-08"}]